The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held ...

MODERNA (MRNA, Financial) secured a major legal win in its COVID-19 vaccine patent dispute with Pfizer (PFE, Financial) and ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...

A German court ruled on Wednesday that BioNTech and Pfizer violated a Covid-19 patent held by rival Moderna. US-based Moderna had asserted claims for information and damages for infringement of its ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

US investor Endeavor Catalyst plans to increase its investments in Africa over the next half decade, potentially doubling the ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Investors might want to bet on BioNTech SE Sponsored ADR (BNTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...